Furthermore, a study published in the Journal of Neuroendocrinology has suggested that the ECS is capable of stimulating specific areas of the body involved in metabolism, such as the skeletal muscles and GI tract. This happens due to the presence of anandamide and 2-AG, which are two naturally-occurring compounds in the body that interact with the CB1 and CB2 receptors.
It’s important to remember, though, that these areas of study are still very new and in their early stages. This makes it hard to predict just how far their reach and impact will be. Combined with lifestyle and dietary changes, prescribed cannabinoid use will very likely be a pivotal intervention in the future of obesity and diabetes management and recovery.